rIB4-SAP References

Cat #IT-10

Molecular Neurosurgery with Targeted Toxins, edited by RG Wiley and DA Lappi

Get Details and Purchase

2018

Watanabe S, Sakurai T, Nakamura S, Miyoshi K, & Sato M. The Combinational Use of CRISPR/Cas9 and Targeted Toxin Technology Enables Efficient Isolation of Bi-Allelic Knockout Non-Human Mammalian Clones. (2018). Int J Mol Sci, 19 (4)

Dose:  Cells were trypsinized 3 days after transfection and approximately 80% were incubated for 30 min at 37°C in a solution (25 mcL) containing 0.5–1.0 mcg IB4-SAP.
Objective:  Most genome editing systems employ transient treatment with selective drugs such as puromycin to obtain the desired genome-edited cells, which often allows some untransfected cells to survive and decreases the efficiency of generating genome-edited cells.  The authors developed a novel targeted toxin-based drug-free selection system for the enrichment of genome-edited cells.
Summary:   Results indicate that a combination of the CRISPR/Cas9 system and targeted toxin technology using IB4-SAP allows efficient enrichment of genome-edited clones, particularly bi-allelic KO clones.

Ferrari LF, Khomula EV, Araldi D, & Levine JD. Cd44 Signaling Mediates High Molecular Weight Hyaluronan-Induced Antihyperalgesia. (2018). J Neurosci, 38 (2):308-321.

Dose:  IB4-SAP was diluted in saline and a dose of 3.2 μg in a volume of 20 μl and administered intrathecally 14 d before experiments.
Objective:  To evaluate priming, at both nociceptor terminals, the effect of local administration of agents that reverse type I (protein translation) or type II [combination of Src and mitogen-activated protein kinase (MAPK)] priming.
Summary:   Fentanyl, acting at the -opioid receptor (MOR), induces hyperalgesia and hyperalgesic priming at both the central and peripheral terminal of nociceptors and this is mediated by endoplasmic reticulum Ca2  signaling.  Priming in the central terminal is type II,  whereas that in the peripheral terminal is type I.  Our findings may provide useful information for the design of drugs with improved therapeutic profiles, selectively disrupting individual MOR signaling pathways, to maintain an adequate long-lasting control of pain.

2017

Havelin J, Imbert I, Sukhtankar D, Remeniuk B, Pelletier I, Gentry J, Okun A, Tiutan T, Porreca F, & King TE. Mediation of Movement-Induced Breakthrough Cancer Pain by Ib4-Binding Nociceptors in Rats. (2017). J Neurosci, 37 (20):5111-5122. PMID:  28438966

Dose:  To determine the effect of eliminating input from IB4-binding fibers, separate groups of rats received spinal administration of IB4-SAP or the control, Blank-SAP (3.2 mcg/20 mcl saline) followed by a 10 mcl flush of saline. Movement of an air bubble placed between drug solution and saline was used to monitor progress of the injection.
Objective:  To define a novel preclinical measure of movement-induced breakthrough pain (BTP) that is observed in the presence of morphine controlling ongoing pain.
Summary:  Novel compounds targeting IB4-binding nociceptors may improve pain management for cancer pain patients and other patient populations suffering from BTP that is inadequately treated by currently available medications.

2016

Araldi D, Ferrari LF, Levine JD. (2016) Gi-Protein Coupled 5-HT1B/D Receptor Agonist Sumatriptan Induces Type I Hyperalgesic Priming. Pain 157(8):1773-82.PMID: 27075428 (Targeting Trends 16q3)

La JH, Feng B, Kaji K, Schwartz ES, Gebhart GF. (2016) Roles of isolectin B4-binding afferents in colorectal mechanical nociception. Pain 157(2):348-354. PMID: 26447707 (Targeting Trends 16q1)

Oyamaguchi A, Abe T, Sugiyo S, Niwa H, Takemura M. (2016) Selective elimination of isolectin B4-binding trigeminal neurons enhanced formalin-induced nocifensive behavior in the upper lip of rats and c-Fos expression in the trigeminal subnucleus caudalis. Neurosci Res 103:40-47. PMID: 26216055 (Targeting Trends 15q4)

Sakurai T, Kamiyoshi A, Kawate H, Mori C, Watanabe S, Tanaka M, Uetake R, Sato M, Shindo T. (2016) A Non-Inheritable Maternal Cas9-Based Multiple-Gene Editing System in Mice. Sci Rep 6:20011. PMID: 26817415 (Targeting Trends 17q1)

2015

Araldi D, Ferrari LF, Levine JD. (2015) Repeated Mu-Opioid Exposure Induces a Novel Form of the Hyperalgesic Priming Model for Transition to Chronic Pain. J Neurosci 35(36):12502-12517. PMID: 26354917 (Targeting Trends 16q1)

Kras JV, Weisshaar CL, Pall PS, Winkelstein BA. (2015) Pain from intra-articular NGF or joint injury in the rat requires contributions from peptidergic joint afferents. Neurosci Lett 604:193-198. PMID: 26240991 (Targeting Trends 15q4)

Ono K, Ye Y, Viet CT, Dang D, Schmidt BL. (2015) TRPV1 expression level in isolectin B4-positive neurons contributes to mouse strain difference in cutaneous thermal nociceptive sensitivity. J Neurophysiol 113(9):3345-3355. (Targeting Trends 15q2)

Saeed AW, Pawlowski SA, Ribeiro-da-Silva A. (2015) Limited changes in spinal lamina I dorsal horn neurons following the cytotoxic ablation of non-peptidergic C-fibers. Mol Pain 11(1):54. PMID: 26353788 (Targeting Trends 15q4)

Sato M, Inada E, Saitoh I, Matsumoto Y, Ohtsuka M, Miura H, Nakamura S, Sakurai T, Watanabe S. (2015) A combination of targeted toxin technology and the piggyBac-mediated gene transfer system enables efficient isolation of stable transfectants in nonhuman mammalian cells. Biotechnol J 10(1):143-153. (Targeting Trends 15q1)

Sato M, Watanabe S. (2015) Drug-free selection of stable transfectants using targeted toxin technology and a vector expressing cell-surface carbohydrate-digesting enzyme. Targeting Trends 16(2).

2014

Alvarez P, Green PG, Levine JD. (2014) Role for monocyte chemoattractant protein-1 in the induction of chronic muscle pain in the rat. Pain 155(6):1161-1167. (Targeting Trends 14q3)

Devesa I, Ferrandiz-Huertas C, Mathivanan S, Wolf C, Lujan R, Changeux JP, Ferrer-Montiel A. (2014) alphaCGRP is essential for algesic exocytotic mobilization of TRPV1 channels in peptidergic nociceptors. Proc Natl Acad Sci U S A 111(51):18345-18350. (Targeting Trends 15q2)

Sato M, Miyoshi K, Nagao Y, Nishi Y, Ohtsuka M, Nakamura S, Sakurai T, Watanabe S. (2014) The combinational use of CRISPR/Cas9-based gene editing and targeted toxin technology enables efficient biallelic knockout of the alpha-1,3-galactosyltransferase gene in porcine embryonic fibroblasts. Xenotransplantation 21(3):291-300. (Targeting Trends 14q3)

Ye Y, Bae S, Viet CT, Troob S, Bernabe D, Schmidt BL. (2014) IB4(+) and TRPV1(+) sensory neurons mediate pain but not proliferation in a mouse model of squamous cell carcinoma. Behav Brain Funct 10(1):5. (Targeting Trends 14q2)

2013

Sato M, Akasaka E, Saitoh I, Ohtsuka M, Nakamura S, Sakurai T, Watanabe S. (2013) Targeted toxin-based selectable drug-free enrichment of Mammalian cells with high transgene expression. Biology (Basel) 2(1):341-355. (Targeting Trends 15q1)

2012

Alvarez P, Chen X, Bogen O, Green PG, Levine JD. (2012) IB4(+) nociceptors mediate persistent muscle pain induced by GDNF. J Neurophysiol 108(9):2545-2553. (Targeting Trends 13q1)

Alvarez P, Gear RW, Green PG, Levine JD. (2012) IB4-saporin attenuates acute and eliminates chronic muscle pain in the rat. Exp Neurol 233(2):859-865. (Targeting Trends 12q2)

Taylor AM, Osikowicz M, Ribeiro-da-Silva A. (2012) Consequences of the ablation of nonpeptidergic afferents in an animal model of trigeminal neuropathic pain. Pain 153(6):1311-1319. (Targeting Trends 12q3)

Tolner EA, Sheikh A, Yukin AY, Kaila K, Kanold PO. (2012) Subplate neurons promote spindle bursts and thalamocortical patterning in the neonatal rat somatosensory cortex. J Neurosci 32(2):692-702. (Targeting Trends 12q2)

Ye Y, Dang D, Viet CT, Dolan JC, Schmidt BL. (2012) Analgesia Targeting IB4-Positive Neurons in Cancer-Induced Mechanical Hypersensitivity. J Pain 13(6):524-531. (Targeting Trends 12q3)

2011

See: Society for Neuroscience 2011 Abstracts

2010

Akasaka E, Watanabe S, Himaki T, Ohtsuka M, Yoshida M, Miyoshi K, Sato M (2010) Enrichment of xenograft-competent genetically modified pig cells using a targeted toxin, isolectin BS-I-B4 conjugate. Xenotransplantation 17:81-89. (Targeting Trends 10q2)

Joseph EK, Levine JD (2010) Mu and delta opioid receptors on nociceptors attenuate mechanical hyperalgesia in rat. Neuroscience 171(1):344-350. (Targeting Trends 10q4)

Joseph EK, Levine JD (2010) Hyperalgesic priming is restricted to isolectin B4-positive nociceptors. Neuroscience 169(1):431-435. (Targeting Trends 10q3)

2009

Bogen O, Dina OA, Gear RW, Levine JD (2009) Dependence of monocyte chemoattractant protein 1 induced hyperalgesia on the isolectin B4-binding protein versican. Neuroscience 159:780-786. (Targeting Trends 09q2)

2008

Bogen O, Joseph EK, Chen X, Levine JD (2008) GDNF hyperalgesia is mediated by PLCgamma, MAPK/ERK, PI3K, CDK5 and Src family kinase signaling and dependent on the IB4-binding protein versican. Eur J Neurosci 28:12-19. (Targeting Trends 08q4)

Joseph EK, Chen X, Bogen O, Levine JD (2008) Oxaliplatin Acts on IB4-Positive Nociceptors to Induce an Oxidative Stress-Dependent Acute Painful Peripheral Neuropathy. J Pain 9:463-472. ((Targeting Trends 08q2)(Targeting Trends 08q2))

Zinck ND, Downie JW (2008) IB4 afferent sprouting contributes to bladder dysfunction in spinal rats. Exp Neurol 213:293-302. (Targeting Trends 08q4)

2007

See: Society for Neuroscience 2007 Abstracts

2005

Lappi DA (2005) Targeted Toxins from Here to There. Targeting Trends 6(3):1, 6.

Pearson M. (2005) IB4-SAP Prevents Axotomy-Induced Sprouting of Aß Fibers. Targeting Trends 6(1).

See: Society for Neuroscience 2005 Abstracts

2004

Nishiguchi J, Sasaki K, Seki S, Chancellor MB, Erickson KA, de Groat WC, Kumon H, Yoshimura N (2004) Effects of isolectin B4-conjugated saporin, a targeting cytotoxin, on bladder overactivity induced by bladder irritation. Eur J Neurosci 20(2):474-482. (Targeting Trends 04q3)

Sedel F, Béchade C, Vyas S, Triller A (2004) Macrophage-derived tumor necrosis factor alpha, an early developmental signal for motoneuron death. J Neurosci 24(9):2236-2246.

Tarpley JW, Kohler MG, Martin WJ (2004) The behavioral and neuroanatomical effects of IB(4)-saporin treatment in rat models of nociceptive and neuropathic pain. Brain Res 1029(1):65-76. (Targeting Trends 05q1)(Targeting Trends 05q1)

Yoshimura N. (2004) Effects of IB4-SAP on Bladder Overactivity. Targeting Trends 5(4).

See also: Society for Neuroscience 2004 Abstracts

2003

Lappi D. (2003) Biotinylated targeting. A viable option? Targeting Trends 4(2).

Nakatsuka T, Tsuzuki K, Ling JX, Sonobe H, Gu JG (2003) Distinct roles of P2X receptors in modulating glutamate release at different primary sensory synapses in rat spinal cord. J Neurophysiol 89(6):3243-3252. (Targeting Trends 03q3)

2001

Vulchanova L, Olson TH, Stone LS, Riedl MS, Elde R, Honda CN (2001) Cytotoxic targeting of isolectin IB4-binding sensory neurons. Neurosci 108(1):143-155. (Targeting Trends 02q2)

See also: Society for Neuroscience 2001 Abstracts

2000

See: Society for Neuroscience 2000 Abstracts

1999

Basbaum AI (1999) Distinct neurochemical features of acute and persistent pain. Proc Natl Acad Sci USA 96:7739-7743.

1998

Snider WD, McMahon SB (1998) Tackling pain at the source: New ideas about nociceptors. Neuron 20:629-632.